FDA approves expanded HYMPAVZI use for hemophilia patients with inhibitors

June 8, 2026 6:45 AM

Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration approved an expanded indication for HYMPAVZI to include patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found